Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Interim Management Statement

2 Oct 2014 07:00

RNS Number : 2305T
Xaar PLC
02 October 2014
 



2 October 2014

 

Xaar plc

 

Interim Management Statement

Xaar plc ("Xaar", "the Group" or "the Company"), the digital inkjet printing technology Group headquartered in Cambridge, UK, is providing an Interim Management Statement covering trading from 1 July 2014.

 

As stated in the Interim Results announcement on 28 August 2014, demand for Xaar's products from the ceramic tile market softened during the third quarter of the year as a result of a slowdown in construction activity in China. The Company's exposure to China is significant, as almost half of the world's ceramic tile output is reported as manufactured and consumed in China. Revenue into the global ceramic tile market represented around two thirds of the Group's sales in 2013.

Monitoring of the ceramic tile market in China has indicated a further decline in activity resulting in excess manufacturing capacity being idled. As a consequence, forecast orders from Xaar's OEMs in this market for the remainder of the year have further reduced, such that the Board now expects total revenue for 2014 to be 5%-10% below the bottom of the previously announced range of £115-125 million.

Although visibility into 2015 remains low, based on all of the information currently available to the Group concerning the ceramic tile market in China, the Group is now planning to take action to reduce costs in anticipation of total Group revenue for 2015 being below £100 million.

Action will be taken immediately to reduce costs in line with the reduced expectation for sales in 2015. This is expected to result in a 15% reduction in operating expenditures, and potentially a total reduction in headcount (subject to consultation) of approximately 20% of the current global workforce of around 800 employees.

The cost reductions aim to achieve a reasonable level of financial operating performance in 2015, whilst ensuring that Xaar can fulfil its key strategic objectives.

Ian Dinwoodie, Chief Executive, commented, "We are highly disappointed to have to make this level of cost reduction given the progress achieved over the last four years. Our exposure to the ceramic tile market in China, which delivered such strong growth over the last few years, is now driving a reduction in our sales. This change re-emphasises the need for Xaar's revenues over time to become more broadly spread across multiple markets and applications. Our competitive position remains strong through our established market leading products, recently announced offerings, and planned future launches. Development efforts on both our Bulk technology and our Thin Film technology provide an excellent basis for our future success as the digitalisation of industrial and commercial printing continues".

A conference call for analysts will take place at 8.00am this morning. The conference call can be accessed by dialling +44 (0)203 139 4830 and using pin code 80375705#.

 

Contacts 

Xaar plc

Ian Dinwoodie, Chief Executive Officer

01223-423663

Alex Bevis, Finance Director

www.xaar.com

Tulchan Communications

Tom Buchanan

Christian Cowley

Victoria Huxster

 

020-7353-4200

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDGXSGBGSB
Date   Source Headline
21st Sep 20239:57 amRNSHolding(s) in Company
19th Sep 20237:00 amRNS2023 Interim Results
11th Sep 20232:11 pmRNSHolding(s) in Company
11th Sep 202312:14 pmRNSHolding(s) in Company
11th Sep 202312:07 pmRNSHolding(s) in Company
11th Sep 202312:03 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
7th Sep 20239:00 amRNSNotice of 2023 Half Year Results
1st Sep 20239:30 amRNSTotal Voting Rights
25th Aug 202312:13 pmRNSHolding(s) in Company
23rd Aug 202310:24 amRNSHolding(s) in Company
18th Aug 202310:30 amRNSChange of Auditor
17th Aug 202312:55 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSTrading Update
1st Aug 20232:00 pmRNSTotal Voting Rights
28th Jul 20234:30 pmRNSHolding(s) in Company
5th Jul 20239:00 amRNSXaar plc - Commercial partnership with Quantica
4th Jul 20233:00 pmRNSBlock listing Interim Review
3rd Jul 20232:53 pmRNSTotal Voting Rights
1st Jun 202310:37 amRNSTotal Voting Rights
31st May 202311:30 amRNSResult of AGM
31st May 20239:00 amRNSBoard Changes
11th May 20235:41 pmRNSHolding(s) in Company
10th May 20233:10 pmRNSDirector/PDMR Shareholding
2nd May 202312:39 pmRNSTotal Voting Rights
24th Apr 20231:05 pmRNSAnnual Financial Report
3rd Apr 20234:51 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSFinal Results
20th Mar 20232:00 pmRNSNotification of the 2022 Full Year Results Date
1st Mar 20233:19 pmRNSTotal Voting Rights
20th Feb 202312:35 pmRNSHolding(s) in Company
1st Feb 202312:30 pmRNSTotal Voting Rights
30th Jan 202312:30 pmRNSHolding(s) in Company
12th Jan 20237:00 amRNSTrading Update
5th Dec 202210:21 amRNSDirector/PDMR Shareholding
1st Dec 202210:19 amRNSTotal Voting Rights
21st Nov 20224:41 pmRNSSecond Price Monitoring Extn
21st Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20221:38 pmRNSGrant of Sharesave Options
1st Nov 202210:41 amRNSTotal Voting Rights
13th Oct 20222:20 pmRNSHolding(s) in Company
3rd Oct 20224:07 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNS2022 INTERIM RESULTS
1st Sep 20225:32 pmRNSTotal Voting Rights
30th Aug 202210:26 amRNSNotice of 2022 Half Year Results
1st Aug 20224:33 pmRNSTotal Voting Rights
1st Aug 202211:25 amRNSHolding(s) in Company
14th Jul 20227:00 amRNSTrading Update
1st Jul 20221:14 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.